Gordon R. B. Skinner
Corporate Officer/Principal presso Vaccine Research International Plc
Profilo
Dr. Gordon R.
Skinner, MD, is a Director & Research Director at Grupo International, Inc. and a Managing Director at Vaccine Research International Plc.
He is on the Board of Directors at Grupo International, Inc. and Intracell Vaccines Ltd.
Dr. Skinner was previously employed as a Board Member & Research Director by HIV-VAC, Inc.
He received his undergraduate degree from the University of Glasgow, a doctorate degree from the University of Birmingham, and a doctorate degree from the University of Birmingham.
Posizioni attive di Gordon R. B. Skinner
| Società | Posizione | Inizio |
|---|---|---|
Vaccine Research International Plc
 Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Corporate Officer/Principal | 09/04/2010 |
Precedenti posizioni note di Gordon R. B. Skinner
| Società | Posizione | Fine |
|---|---|---|
HIV-VAC, Inc.
 HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Direttore Tecnico/Scientifico/R&S | 28/10/2010 |
| GRUPO INTERNATIONAL INC. | Direttore Tecnico/Scientifico/R&S | - |
Intracell Vaccines Ltd.
 Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Direttore/Membro del Consiglio | - |
Formazione di Gordon R. B. Skinner
| University of Glasgow | Undergraduate Degree |
| University of Birmingham | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GRUPO INTERNATIONAL INC. | Health Technology |
| Aziende private | 3 |
|---|---|
HIV-VAC, Inc.
HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Commercial Services |
Intracell Vaccines Ltd.
Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Health Technology |
Vaccine Research International Plc
Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Commercial Services |
- Borsa valori
- Insiders
- Gordon R. B. Skinner